VIDEO: ‘Promising’ treatment for alcoholic hepatitis in development
In this exclusive video, Steven Flamm, MD, chief of the liver program at the Northwestern Feinberg School of Medicine, discusses a potential treatment for alcoholic hepatitis that is currently in development.
Although its been known for decades, there are no approved therapies for alcoholic hepatitis. Flamm said that 1-month mortality rates for patients with acute alcoholic hepatitis can be as high as 40%.
Flamm said one drug currently in development, DUR-928 (Durect), has demonstrated good tolerability in previous research. He said that research presented at The Digital International Liver Congress explored pharmacokinetics of the drug and identified appropriate dosing levels in a phase 2b trial.